Wells Fargo
OKUR

Wells Fargo’s OnKure Therapeutics OKUR Stock Holding History

Wells Fargo’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.9K Buy
13,500
+2,500
+23% +$7.72K ﹤0.01% 5420
2025
Q4 		$31.9K Buy
11,000
+1,500
+16% +$4.49K ﹤0.01% 5676
2025
Q3 		$26.1K Buy
9,500
+1,880
+25% +$4.66K ﹤0.01% 5732
2025
Q2 		$18.2K Buy
7,620
+4,000
+110% +$10.5K ﹤0.01% 5807
2025
Q1 		$15.6K Buy
3,620
+2,000
+123% +$11.2K ﹤0.01% 5775
2024
Q4 		$13.9K Buy
1,620
+1,500
+1,250% +$22.7K ﹤0.01% 5855
2024
Q3 		$2.04K Hold
120
– – ﹤0.01% 6053
2024
Q2 		$1.81K Sell
120
-412
-77% -$6.98K ﹤0.01% 6030
2024
Q1 		$8.84K Buy
532
+50
+10% +$825 ﹤0.01% 5791
2023
Q4 		$7.71K Buy
482
+24
+5% +$1.5K ﹤0.01% 5895
2023
Q3 		$34.9K Sell
458
-114
-20% -$7.75K ﹤0.01% 5364
2023
Q2 		$37.5K Buy
572
+446
+354% +$35.9K ﹤0.01% 5539
2023
Q1 		$7.56K Hold
126
– – ﹤0.01% 5939
2022
Q4 		$2.94K Hold
126
– – ﹤0.01% 5913
2022
Q3 		$4K Buy
126
+2
+2% +$66 ﹤0.01% 5996
2022
Q2 		$3K Sell
124
-412
-77% -$9.59K ﹤0.01% 6244
2022
Q1 		$16K Sell
536
-262
-33% -$14.7K ﹤0.01% 6110
2021
Q4 		$68K Buy
+798
New +$58.6K ﹤0.01% 5828

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wells Fargo's OKUR Position: Q1 2026 in Review

Wells Fargo increased its OnKure Therapeutics (OKUR) stake by 23% in Q1 2026, buying an estimated $7.72K and bringing the position to 13,500 shares worth $55.9K. The position accounts for ﹤0.01% of the portfolio, ranked #5420.

Wells Fargo first reported a position in OKUR in Q4 2021 and has held it in 18 quarters since. The position peaked at $68K in Q4 2021. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

  • Wells Fargo held 13,500 shares of OnKure Therapeutics worth $55.9K as of Q1 2026.
  • Wells Fargo bought 2,500 OnKure Therapeutics shares in Q1 2026, an estimated $7.72K.
  • OnKure Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5420 holding.
  • Wells Fargo first reported a position in OnKure Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Wells Fargo's OnKure Therapeutics position peaked at $68K in Q4 2021.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.